TransCode Therapeutics Inc. (RNAZ) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Over the last few weeks, the stock market had seen the largest monthly decline since the COVID-19 pandemic. Of course, the ...

NSC's first-quarter 2025 top line is expected to have been significantly affected by weak freight demand and tariff-related ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Mirion Technologies (MIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Qorvo (QRVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Zacks Rank is a unique, proprietary stock-rating model that utilizes earnings estimate revisions to help investors build a winning portfolio. There are four main factors behind the Zacks Rank ...

Over the last few weeks, the stock market had seen the largest monthly decline since the COVID-19 pandemic. Of course, the post-pandemic recovery would end up making the COVID-19 plunge one of ...